Platinium VR 1210, Platinium VR 1240, ENERGYA VR 3110, TALENTIA VR 3210, ENERGYA VR 3140, TALENTIA VR 3240, Platinium DR
MicroPort CRM S.r.l. · Decision date Jul 23, 2025
What did the FDA approve?
FDA records P980049/S147 as a supplement to PMA P980049, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 23, 2025.
FDA approval order statement
Approval for the addition of Mylar spacers to our ALIZEA/CELEA pacemakers, allow hybrid tab replacements to occur at Microports Saluggia, Italy facility, and changes in manufacturing processes of other MicroPorts pacemaker, ICD, and CRT-D systems.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 23, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P980049/S147
- Regulatory pathway
- PMA supplement
- Applicant
- MicroPort CRM S.r.l.
- Product code
- MRM
- Decision code
- APPR
- Decision date
- Jul 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- MicroPort CRM S.r.l.
- Product code
- MRM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P980049/S147 received
Application receipt date recorded by FDA.
P980049/S147 · FDA decision
Normal 180 Day Track
P980049/S146 · Related supplement
ENERGYA/TALENTIA ICDs & CRT-Ds, SmartTouch Programmer Software Modules, SmartView Connect App, & RMS
Timeline entries are records held by MedtechLedger for P980049. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980049
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| MicroPort CRM S.r.l. | PMA supplement | Nov 25, 2025 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
BIOexpressP050023/S209 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MicroPort CRM S.r.l.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Via Crescentino S.N., Saluggia, 13040
Sources and methodology
- Original FDA record: P980049/S147
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



